Sweden Medical Device Regulations 2026: EU MDR and MPA Requirements
Manufacturers looking to market medical devices in Sweden in 2026 must comply with EU MDR 2017/745, meet EUDAMED registration requirements, and operate under the oversight of Sweden’s national competent authority. Sweden’s healthcare system is advanced and well-regulated, making thorough compliance planning essential for market access. Demand for innovative devices is strong, particularly in orthopedics, implantables, age-related therapies, and non-invasive technologies.
Who Regulates Medical Devices in Sweden?
Medical devices in Sweden are regulated by the Medical Products Agency (MPA), known in Swedish as Läkemedelsverket. MPA operates under the Ministry of Health and Social Affairs and is responsible for market surveillance and inspections, vigilance and serious incident reporting, supervision of economic operators, clinical investigation oversight, and enforcement of EU MDR and IVDR at the national level. In addition to EU MDR, manufacturers should be aware that Sweden has enacted supplementary national legislation, including the Act (2021:600) and Ordinance (2021:631) with supplementary rules to the EU Regulations on medical devices, which complement the MDR and IVDR frameworks at the national level.
CE Marking Under EU MDR
CE marking under EU MDR is mandatory to place a device on the Swedish market. Devices are classified as Class I, IIa, IIb, or III. Class I devices that are non-sterile, have no measuring function, and are not reusable surgical instruments may be self-declared by the manufacturer. All other device classes require Notified Body involvement in the conformity assessment process. Clinical evaluation requirements are significantly strengthened under MDR, and post-market surveillance obligations are expanded for all device classes. A Quality Management System aligned with ISO 13485 and risk management aligned with ISO 14971 are expected. Once CE marked, devices may be marketed freely throughout the EU and EEA, including Sweden.
EUDAMED Registration: Critical 2026 Deadlines
From May 28, 2026, EUDAMED registration is mandatory for four confirmed functional modules: economic operator registration, UDI and device registration, Notified Bodies and certificates, and market surveillance. New devices must be registered in EUDAMED before being placed on the market from May 28, 2026 onward. Devices already on the market before that date must be registered in EUDAMED by November 28, 2026.
Prior to the May 28, 2026 deadline, the primary registration of operators and devices must be carried out with the Swedish MPA, and certain categories must also continue to be registered with the Swedish MPA even after EUDAMED becomes mandatory. Specifically, manufacturers of custom-made devices and national medical information systems (NMI) must continue to register directly with the Swedish MPA regardless of EUDAMED status. Operators repackaging or relabeling devices must also remain registered with MPA.
Importantly, economic operators outside Sweden do not need to register with the MPA if they are already registered with a competent authority in another EU/EEA member state.
Non-EU manufacturers must appoint an EU Authorized Representative, who holds legally defined responsibilities under MDR and serves as the primary point of contact for MPA and other national competent authorities.
Manufacturers should also monitor the European Commission’s ongoing review of the MDR and IVDR frameworks for targeted simplification, as amendments may affect specific compliance obligations during 2026 and beyond.
Language and Labeling Requirements
Every user of a medical device in Sweden must have access to information written in Swedish on the labeling and in the Instructions for Use. Information submitted to MPA may be provided in Swedish or English. UDI labeling must comply with MDR standards, and critical warnings must be presented clearly and in full. Failure to meet language and labeling requirements can delay market access or trigger corrective actions from MPA.
Clinical Investigations in Sweden (2026 Framework)
To conduct a clinical investigation of a medical device in Sweden, approval from the Swedish MPA or the Swedish Ethical Review Authority is required, depending on the type of authorization procedure being used. Where human biological samples regulated by the Biobanks Act (2023:38) are included in the study, a biobank application with approval by the biobank custodian is also required. Applications and notifications for clinical investigations are currently handled nationally by MPA, as the relevant EUDAMED module for clinical investigations is not yet operational. MDR-aligned documentation and safety reporting standards apply throughout. Sweden’s well-established clinical research infrastructure makes it a preferred location for innovative device trials, provided full MDR compliance is maintained.
Post-Market Surveillance and Vigilance
Post-market obligations are a central part of MDR enforcement in Sweden and are actively monitored by MPA. The National Board of Health and Welfare additionally mandates that healthcare providers in Sweden report device incidents to MPA. Manufacturers must maintain a documented Post-Market Surveillance plan, Periodic Safety Update Reports for Class IIb and III devices (Class IIa devices have separate periodic reporting obligations under MDR Article 86), UDI-based traceability, and Field Safety Corrective Action procedures. Timely reporting of serious incidents is required, and initial reports may be submitted and later amended with updated information as investigations progress. Centralized management of post-market data across multiple EU markets is essential for maintaining audit readiness.
Sweden Medical Device Market Overview
Sweden is a strategically valuable EU market due to its advanced healthcare infrastructure, aging population, and strong demand for orthopedics, implantable devices, age-related therapies, and digital health technologies. Foreign manufacturers benefit from streamlined EU-wide CE marking, though local regulatory compliance, including MPA registration obligations and Swedish language requirements, remains essential.
Key Takeaways for 2026
To successfully commercialize a medical device in Sweden, manufacturers should ensure full compliance with EU MDR and Sweden’s supplementary national legislation, obtain valid CE marking, complete EUDAMED economic operator and device registration ahead of the May 28, 2026 mandatory deadline (with legacy devices requiring registration by November 28, 2026), confirm whether direct MPA registration is still required for their device category, appoint an EU Authorized Representative if located outside the EU, meet Swedish language and labeling requirements, implement structured post-market surveillance and vigilance processes including PSURs where required under MDR Article 86, and monitor European Commission MDR simplification discussions for developments that may affect compliance obligations. With MDR enforcement fully in effect, centralized regulatory systems and proactive compliance planning are critical for successful EU market access.
